Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 94 of 119 for:    ZIRCONIUM

Zr-89 Cimzia PET Imaging Rheumatoid Arthritis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03546335
Recruitment Status : Recruiting
First Posted : June 5, 2018
Last Update Posted : October 11, 2018
Sponsor:
Information provided by (Responsible Party):
Benjamin Franc, MD, MBA, University of California, San Francisco

Brief Summary:
This is a single center exploratory imaging study investigating the initial application of 89Zr-DFO-CZP PET in patients with rheumatoid arthritis. Patients with active symptoms of RA or signs on physical exam will be invited to participate for PET imaging.

Condition or disease Intervention/treatment Phase
Rheumatoid Arthritis Drug: 89Zr-DFO-CZP Phase 1

Detailed Description:
This is a single center exploratory imaging study investigating the initial application of 89Zr-DFO-CZP PET in patients with rheumatoid arthritis. Patients with active symptoms of RA or signs on physical exam will be invited to participate for PET imaging. Study 1 is a dose finding study that will involve a single 89Zr-DFO-CZP PET scan acquired ~24 hours following a single administration of the radiopharmaceutical. The first 2 patients will receive 1 mCi of 89Zr-DFO-CZP. Subsequent groups of two patients will receive 0.5 mCi decrease or increase dose (up to 2 mCi) to determine the acceptable optimal imaging dose.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: The first 2 patients will receive 1 mCi of 89Zr-DFO-CZP. Subsequent groups of two patients will receive 0.5 mCi decrease or increase dose (up to 2 mCi) to determine the acceptable optimal imaging dose.
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Zirconium-89 Certolizumab PET Imaging in Patients With Rheumatoid Arthritis
Actual Study Start Date : October 1, 2018
Estimated Primary Completion Date : March 31, 2020
Estimated Study Completion Date : April 1, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: 1mCi injection of 89Zr-DFO-CZP
The first 2 patients will receive 1mCi of 89Zr-DFO-CZP.
Drug: 89Zr-DFO-CZP
89Zr-DFO-Certolizumab pegol (89Zr-DFO-CZP) is a radiopharmaceutical imaging agent that will be produced under CGMP (Current Good Manufacturing Practice) regulations in the Department of Radiology and Biomedical Imaging Radiopharmaceutical Facility at UCSF.
Other Name: 89Zr-Cimzia

Experimental: 0.5mCi injection of 89Zr-DFO-CZP
Subsequent groups of two patients will receive 0.5 mCi decrease or increase dose (up to 2 mCi) to determine the acceptable optimal imaging dose.
Drug: 89Zr-DFO-CZP
89Zr-DFO-Certolizumab pegol (89Zr-DFO-CZP) is a radiopharmaceutical imaging agent that will be produced under CGMP (Current Good Manufacturing Practice) regulations in the Department of Radiology and Biomedical Imaging Radiopharmaceutical Facility at UCSF.
Other Name: 89Zr-Cimzia

Experimental: 1.5mCi injection of 89Zr-DFO-CZP
Subsequent groups of two patients will receive 0.5 mCi decrease or increase dose (up to 2 mCi) to determine the acceptable optimal imaging dose.
Drug: 89Zr-DFO-CZP
89Zr-DFO-Certolizumab pegol (89Zr-DFO-CZP) is a radiopharmaceutical imaging agent that will be produced under CGMP (Current Good Manufacturing Practice) regulations in the Department of Radiology and Biomedical Imaging Radiopharmaceutical Facility at UCSF.
Other Name: 89Zr-Cimzia

Experimental: 2mCi injection of 89Zr-DFO-CZP
Subsequent groups of two patients will receive 0.5 mCi decrease or increase dose (up to 2 mCi) to determine the acceptable optimal imaging dose.
Drug: 89Zr-DFO-CZP
89Zr-DFO-Certolizumab pegol (89Zr-DFO-CZP) is a radiopharmaceutical imaging agent that will be produced under CGMP (Current Good Manufacturing Practice) regulations in the Department of Radiology and Biomedical Imaging Radiopharmaceutical Facility at UCSF.
Other Name: 89Zr-Cimzia




Primary Outcome Measures :
  1. Uptake of 89Zr-DFO-CZP taken up in symptomatic versus asymptomatic joints of patients with rheumatoid arthritis (RA). [ Time Frame: 2 years ]
    Investigators will be evaluating whether 89Zr-DFO-CZP is taken up in symptomatic versus asymptomatic joints of patients with rheumatoid arthritis (RA).


Secondary Outcome Measures :
  1. Uptake of 89Zr-DFO-CZP in symptomatic joints of patients with rheumatoid arthritis after administration of a TNF-alpha inhibitor therapeutic. [ Time Frame: 2 years ]
    Investigators will be evaluating the uptake of 89Zr-DFO-CZP in symptomatic joints of patients with rheumatoid arthritis after administration of a TNF-alpha inhibitor therapeutic.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age > 18 years old
  2. Ability to read and understand written informed consent document
  3. Patients with clinical diagnosis of rheumatoid arthritis

Exclusion Criteria:

  1. For patients planning to be imaged on PET-MR scanner, exclusion criteria will include any contra-indication to MRI, including permanent pacemaker, implantable metallic device/ prosthetic, aneurysm clip, non-removable piercing, or severe claustrophobia
  2. Any medical condition that would compromise the imaging acquisition, in the opinion of the investigator
  3. Patients who have had a study involving radiation within one year of enrolling in this study
  4. Patients who are pregnant (female patients of childbearing age will be tested prior to injection of imaging agent - positive test will exclude from participating in the study)
  5. Patients who are breastfeeding
  6. Patients who cannot confirm that they will use reliable contraceptive methods for 90 days
  7. Patients treated with TNF - α inhibitor therapy
  8. Females of child-bearing age (<50 years old), until data from the dose-finding study has been reviewed by the UCSF Radiation Safety Committee and explicit written permission has been provided by the UCSF Radiation Safety Committee to open the window of potential female participants to ages 18 years and older.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03546335


Contacts
Layout table for location contacts
Contact: I-Wei Wu 415-353-9437 Katherine.wu@ucsf.edu

Locations
Layout table for location information
United States, California
UCSF Recruiting
San Francisco, California, United States, 94107
Contact: I-Wei Wu    415-353-9437    Katherine.wu@ucsf.edu   
Principal Investigator: Benjamin Franc, MD         
Sponsors and Collaborators
University of California, San Francisco
Investigators
Layout table for investigator information
Principal Investigator: Benjamin Franc, MD/MBA University of California, San Francisco

Layout table for additonal information
Responsible Party: Benjamin Franc, MD, MBA, Professor, Department of Radiology, University of California, San Francisco
ClinicalTrials.gov Identifier: NCT03546335     History of Changes
Other Study ID Numbers: 17-23566
First Posted: June 5, 2018    Key Record Dates
Last Update Posted: October 11, 2018
Last Verified: October 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Arthritis
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Certolizumab Pegol
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents